Table 1 Baseline characteristics
Characteristic | ACE-27 low (0–1) | ACE-27 high (2–3) | p value |
|---|---|---|---|
n = 171 | n = 51 | ||
Age (median (IQR)) | 68 (66,72) | 71 (66,75) | 0.06 |
BMI (median (IQR)) | 22.86 (20.31,25.78) | 22.27 (20.30,24.62) | 0.314 |
ECOG | |||
 0 n(%) | 84 (49.12) | 16 (31.37) | 0.001 |
 1 n(%) | 65 (38.01) | 17 (33.33) |  |
  ≥ 2 n(%) | 22 (12.86) | 18 (35.29) |  |
FIGO stage | |||
 IIB n(%) | 20 (11.69) | 1 (1.960) | 0.034* |
 III n(%) | 101 (59.06) | 37 (72.54) |  |
 IV n(%) | 37 (21.63) | 7 (13.72) |  |
Histology | |||
 Serous n(%) | 140 (81.87) | 33 (64.70) | 0.001* |
 Mucinous n(%) | 8 (4.678) | 5 (9.803) |  |
 Endometrioid n(%) | 4 (2.339) | 5 (9.803) |  |
 Clear n(%) | 1 (0.584) | 4 (7.843) |  |
 Mixed + others n(%) | 18 (10.52) | 4 (7.843) |  |
Albumin | |||
  < 30 g/L n(%) | 15 (8.771) | 9 (17.64) | 0.109 |
 30 ~ 35 g/L n(%) | 35 (20.46) | 7 (13.72) |  |
  > 35 g/L n(%) | 78 (45.61) | 19 (37.25) |  |
CA125 | |||
  < 600 n(%) | 56 (32.74) | 17 (33.33) | 0.383 |
  ≥ 600 n(%) | 91 (53.21) | 20 (39.21) |  |
Treatment | |||
 no-CRS n(%) | 39 (22.80) | 19 (37.25) | 0.039 |
 CRS n(%) | 132 (77.19) | 32 (62.74) |  |